WO2002053099A3 - Methodes et compositions de traitement d'une parodontopathie - Google Patents

Methodes et compositions de traitement d'une parodontopathie Download PDF

Info

Publication number
WO2002053099A3
WO2002053099A3 PCT/US2001/049638 US0149638W WO02053099A3 WO 2002053099 A3 WO2002053099 A3 WO 2002053099A3 US 0149638 W US0149638 W US 0149638W WO 02053099 A3 WO02053099 A3 WO 02053099A3
Authority
WO
WIPO (PCT)
Prior art keywords
periodontal disease
methods
compositions
present
treating periodontal
Prior art date
Application number
PCT/US2001/049638
Other languages
English (en)
Other versions
WO2002053099A2 (fr
Inventor
George D Hartman
Sevgi B Rodan
Gideon A Rodan
Original Assignee
Merck & Co Inc
George D Hartman
Sevgi B Rodan
Gideon A Rodan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, George D Hartman, Sevgi B Rodan, Gideon A Rodan filed Critical Merck & Co Inc
Priority to US10/250,546 priority Critical patent/US20040053968A1/en
Priority to AU2002246757A priority patent/AU2002246757B2/en
Priority to JP2002554050A priority patent/JP2004517853A/ja
Priority to EP01994350A priority patent/EP1349548A4/fr
Priority to CA002432504A priority patent/CA2432504A1/fr
Publication of WO2002053099A2 publication Critical patent/WO2002053099A2/fr
Publication of WO2002053099A3 publication Critical patent/WO2002053099A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)

Abstract

La présente invention concerne une méthode de traitement d'une perte osseuse alvéolaire provoquée par une parodontopathie consistant à administrer une quantité efficace thérapeutiquement d'un antagoniste de récepteur d'intégrine αvβ3 mélangée à une quantité efficace thérapeutiquement d'un inhibiteur COX-2, chez un sujet nécessitant un tel traitement. En outre, cette invention a trait à des compositions pharmaceutiques utilisées dans les méthodes susmentionnées, ainsi qu'à un procédé d'élaboration d'un médicament destiné au traitement de la perte osseuse alvéolaire provoquée par une parodontopathie.
PCT/US2001/049638 2001-01-03 2001-12-28 Methodes et compositions de traitement d'une parodontopathie WO2002053099A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/250,546 US20040053968A1 (en) 2001-12-28 2001-12-28 Methods and compositions for treating peridontal disease
AU2002246757A AU2002246757B2 (en) 2001-01-03 2001-12-28 Methods and compositions for treating periodontal disease
JP2002554050A JP2004517853A (ja) 2001-01-03 2001-12-28 歯周病の治療方法及び治療用組成物
EP01994350A EP1349548A4 (fr) 2001-01-03 2001-12-28 Methodes et compositions de traitement d'une parodontopathie
CA002432504A CA2432504A1 (fr) 2001-01-03 2001-12-28 Methodes et compositions de traitement d'une parodontopathie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25944101P 2001-01-03 2001-01-03
US60/259,441 2001-01-03

Publications (2)

Publication Number Publication Date
WO2002053099A2 WO2002053099A2 (fr) 2002-07-11
WO2002053099A3 true WO2002053099A3 (fr) 2002-09-12

Family

ID=22984959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049638 WO2002053099A2 (fr) 2001-01-03 2001-12-28 Methodes et compositions de traitement d'une parodontopathie

Country Status (5)

Country Link
EP (1) EP1349548A4 (fr)
JP (1) JP2004517853A (fr)
AU (1) AU2002246757B2 (fr)
CA (1) CA2432504A1 (fr)
WO (1) WO2002053099A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
EP4249471A3 (fr) 2013-09-24 2023-10-18 FUJIFILM Corporation Composition pharmaceutique d'un composé contenant de l'azote ou son sel ou son complexe métallique
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190981A (en) * 1989-08-17 1993-03-02 Sepracor Inc. Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031099A1 (fr) * 1997-12-17 1999-06-24 Merck & Co., Inc. Antagonistes du recepteur de l'integrine
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
EP1100506A4 (fr) * 1998-07-29 2002-06-26 Merck & Co Inc Antagonistes des recepteurs de l'integrine
HUP0302468A2 (hu) * 1999-06-02 2003-11-28 Merck & Co., Inc. Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190981A (en) * 1989-08-17 1993-03-02 Sepracor Inc. Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1349548A4 *

Also Published As

Publication number Publication date
EP1349548A4 (fr) 2004-06-02
WO2002053099A2 (fr) 2002-07-11
EP1349548A2 (fr) 2003-10-08
AU2002246757B2 (en) 2006-02-02
CA2432504A1 (fr) 2002-07-11
JP2004517853A (ja) 2004-06-17

Similar Documents

Publication Publication Date Title
IS6557A (is) Blandaðar sjúkdómsmeðferðir úr blóðþrýstingslækkandi efnum og efnum sem hamla æðamyndun
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
CA2427227A1 (fr) Compose de lactam
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
HUP0303876A3 (en) Preparation of pharmaceutical compositions for treatment of type 2 diabetes using piperidine or tiazolidine, inhibitors of dipeptidyl peptidase iv
UA89615C2 (ru) Фармацевтические композиции, которые содержат никотиновую кислоту и антагонист рецептора dp
WO2004091540A3 (fr) Methodes de traitement de la douleur et compositions associees
WO2001001972A3 (fr) ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
WO2002088100A3 (fr) 3-piperidinopropiophenones dopees et produits pharmaceutiques contenant ces composes
WO2001041754A3 (fr) Inhibiteurs d'agregation plaquettaire induite par le collagene
WO2003080125A3 (fr) Medicaments
EP1064966A3 (fr) Combinaisons d'agonistes de recepteurs de 5HT 1, de cafeine et d'inhibiteurs de cyclooxygenase-2 pour le traitement de la migraine
EP1262197A3 (fr) Combinaison thérapeutique pour traiter les troubles du sommeil, y compris l'apnée du sommeil
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2006015970A3 (fr) Medicaments pour la prevention ou le traitement de la pneumonie alveolaire comprenant un anticholinergique
WO2002053099A3 (fr) Methodes et compositions de traitement d'une parodontopathie
WO2003015690A3 (fr) Methode de traitement de l'insomnie primaire
SE9902597D0 (sv) New use
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
WO2002069944A3 (fr) Nouvelles compositions medicamenteuses a base d'anticholinergiques et d'antagonistes de recepteurs nk1
SE0000303D0 (sv) Novel compounds
WO2002055022A3 (fr) Metabolite actif de compose antifongique
MXPA02012574A (es) Uso novedoso de los antagonistas ii de angiotensina.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2432504

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002246757

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001994350

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10250546

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002554050

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001994350

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 2001994350

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001994350

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002246757

Country of ref document: AU